Inovio Pharmaceuticals, Inc. (INO)
1.27
-0.02
(-1.55%)
USD |
NASDAQ |
Aug 31, 16:00
1.27
0.00 (0.00%)
After-Hours: 20:00
Inovio Pharmaceuticals Cash from Operations (TTM) : -80.58M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -80.58M |
| March 31, 2026 | -83.35M |
| December 31, 2025 | -88.63M |
| September 30, 2025 | -88.92M |
| June 30, 2025 | -94.79M |
| March 31, 2025 | -102.19M |
| December 31, 2024 | -104.08M |
| September 30, 2024 | -110.69M |
| June 30, 2024 | -112.36M |
| March 31, 2024 | -116.46M |
| December 31, 2023 | -124.37M |
| September 30, 2023 | -134.43M |
| June 30, 2023 | -172.78M |
| March 31, 2023 | -191.00M |
| December 31, 2022 | -216.22M |
| September 30, 2022 | -217.77M |
| June 30, 2022 | -196.79M |
| March 31, 2022 | -224.72M |
| December 31, 2021 | -215.71M |
| September 30, 2021 | -229.03M |
| June 30, 2021 | -256.70M |
| March 31, 2021 | -205.39M |
| December 31, 2020 | -177.98M |
| September 30, 2020 | -140.50M |
| June 30, 2020 | -94.08M |
| Date | Value |
|---|---|
| March 31, 2020 | -90.85M |
| December 31, 2019 | -97.85M |
| September 30, 2019 | -101.39M |
| June 30, 2019 | -98.33M |
| March 31, 2019 | -93.43M |
| December 31, 2018 | -73.55M |
| September 30, 2018 | -70.22M |
| June 30, 2018 | -62.86M |
| March 31, 2018 | -60.56M |
| December 31, 2017 | -63.21M |
| September 30, 2017 | -64.16M |
| June 30, 2017 | -65.49M |
| March 31, 2017 | -62.04M |
| December 31, 2016 | -62.56M |
| September 30, 2016 | -54.43M |
| June 30, 2016 | -20.36M |
| March 31, 2016 | -16.11M |
| December 31, 2015 | -12.44M |
| September 30, 2015 | -13.84M |
| June 30, 2015 | -37.31M |
| March 31, 2015 | -36.44M |
| December 31, 2014 | -29.92M |
| September 30, 2014 | -20.87M |
| June 30, 2014 | -18.53M |
| March 31, 2014 | -15.81M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Fortress Biotech, Inc. | 120.36M |
| Tonix Pharmaceuticals Holding Corp. | -155.18M |
| Kura Oncology, Inc. | -111.76M |
| Spero Therapeutics, Inc. | 19.58M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |